159 related articles for article (PubMed ID: 1322029)
1. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Khan S; Mehta JL
Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
[TBL] [Abstract][Full Text] [Related]
2. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
[TBL] [Abstract][Full Text] [Related]
3. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
4. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
[TBL] [Abstract][Full Text] [Related]
5. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
[TBL] [Abstract][Full Text] [Related]
6. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
7. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
8. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
[TBL] [Abstract][Full Text] [Related]
9. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
[TBL] [Abstract][Full Text] [Related]
10. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
Sakamoto T; Ogawa H; Yasue H; Oda Y; Kitajima S; Tsumoto K; Mizokami H
Circulation; 1994 Jul; 90(1):427-32. PubMed ID: 8026029
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
Mickelson JK; Simpson PJ; Cronin M; Homeister JW; Laywell E; Kitzen J; Lucchesi BR
Circulation; 1990 Feb; 81(2):617-27. PubMed ID: 2105175
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Shebuski RJ; Stabilito IJ; Sitko GR; Polokoff MH
Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
[TBL] [Abstract][Full Text] [Related]
13. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
14. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
[TBL] [Abstract][Full Text] [Related]
15. Prevention of reocclusion following tissue type plasminogen activator-induced thrombolysis by the RGD-containing peptide, echistatin, in a canine model of coronary thrombosis.
Holahan MA; Mellott MJ; Garsky VM; Shebuski RJ
Pharmacology; 1991; 42(6):340-8. PubMed ID: 1946598
[TBL] [Abstract][Full Text] [Related]
16. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
17. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis.
Yasuda T; Gold HK; Fallon JT; Leinbach RC; Garabedian HD; Guerrero JL; Collen D
J Am Coll Cardiol; 1989 May; 13(6):1409-14. PubMed ID: 2495318
[TBL] [Abstract][Full Text] [Related]
18. Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Mehta JL; Chen L; Nichols WW; Johannesen M; BregengÄrd C; Hedner U; Saldeen TG
J Am Coll Cardiol; 1995 Mar; 25(3):753-60. PubMed ID: 7860925
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
Shebuski RJ; Sitko GR; Claremon DA; Baldwin JJ; Remy DC; Stern AM
Blood; 1990 Apr; 75(7):1455-9. PubMed ID: 1969293
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
Nicolini FA; Mehta JL; Nichols WW; Saldeen TG; Grant M
Circulation; 1990 Mar; 81(3):1115-22. PubMed ID: 1689620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]